Key result
In STZ-induced diabetic rats, impairment of vasodilatation to exogenous NO was transient, and non-NO-, non-prostanoid-dependent vasodilatation and K(+) channel activity were augmented.
In a rat model of STZ-induced diabetes, alterations in NO bioactivity were transient and unrelated to the development of diabetic sensory neuropathy, whereas non-NO-, non-prostanoid-dependent vasodilatation and K+ channel activity were augmented.
Findings in diabetic rats are hypothesis-generating; leaves open whether augmented K+ channel activity protects against human neuropathy.
This study examined NO- and non-NO-, non-prostanoid-dependent pathways of agonist-induced vasodilatation in streptozotocin (STZ)-induced diabetic rats and their age-matched controls at 1-2, 8-10 and 18-20 weeks after induction of diabetes. Using laser Doppler flowmetry, vasodilatory responses to acetylcholine (ACh; 0.1 mM) and morpholino-sydnonimine (SIN-1) were determined in the presence of Ringer solution, during inhibition of NO synthase (NOS) and cyclo-oxygenase (COX) with N(omega)-nitro-L-arginine (L-NNA; 1 mM) + indomethacin (10(-5) M), and during inhibition of K(+) channels, NOS and COX with tetraethylammonium (TEA; 10 mM) + L-NNA + indomethacin. Basal NOS activity and nerve conduction velocity were also determined. In age-matched controls, SIN-1-induced vasodilatation in the presence of TEA + L-NNA + indomethacin, basal NOS activity and the initial vasodilatory response to ACh during NOS and COX inhibition all decreased with maturation. In STZ-induced diabetics, SIN-1-induced vasodilatation in the presence of TEA + L-NNA + indomethacin was impaired immediately after induction of diabetes, but not at 18-20 weeks. NOS activity in STZ-induced diabetics displayed a transient 2-fold increase at 8-10 weeks, decreasing to age-matched control levels at 18-20 weeks. At 18-20 weeks of STZ-induced diabetes, ACh-induced vasodilatation during NOS and COX inhibition was prolonged due to increased K(+) channel activity and experimental diabetic sensory neuropathy (EDN) had developed. Thus, in sciatic nerve microcirculation of STZ-induced diabetic rats: (1) diabetic impairment of vasodilatation in response to exogenous NO was transient; (2) non-NO-, non-prostanoid-dependent vasodilatation and K(+) channel activity were augmented in STZ-induced diabetes; and (3) alterations in NO bioactivity were not related to the development of EDN.
No takes yet. Share an insight, caveat, or question.
Rubin et al. (2002) studied Experimental diabetic neuropathy. Streptozotocin (STZ)-induced diabetes vs. Age-matched controls was evaluated on NO- and non-NO-, non-prostanoid-dependent pathways of agonist-induced vasodilatation. In STZ-induced diabetic rats, impairment of vasodilatation to exogenous NO was transient, and non-NO-, non-prostanoid-dependent vasodilatation and K(+) channel activity were augmented.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: